Risk factors for recurrent C lostridium difficile infection in hematopoietic stem cell transplant recipients
dc.contributor.author | Huang, A.M. | en_US |
dc.contributor.author | Marini, B.L. | en_US |
dc.contributor.author | Frame, D. | en_US |
dc.contributor.author | Aronoff, D.M. | en_US |
dc.contributor.author | Nagel, J.L. | en_US |
dc.date.accessioned | 2014-11-04T16:35:13Z | |
dc.date.available | WITHHELD_12_MONTHS | en_US |
dc.date.available | 2014-11-04T16:35:13Z | |
dc.date.issued | 2014-10 | en_US |
dc.identifier.citation | Huang, A.M.; Marini, B.L.; Frame, D.; Aronoff, D.M.; Nagel, J.L. (2014). "Risk factors for recurrent C lostridium difficile infection in hematopoietic stem cell transplant recipients." Transplant Infectious Disease 16(5): 744-750. | en_US |
dc.identifier.issn | 1398-2273 | en_US |
dc.identifier.issn | 1399-3062 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/109272 | |
dc.description.abstract | Background Recurrent C lostridium difficile infection ( CDI ) represents a significant burden on the healthcare system and is associated with poor outcomes in hematopoietic stem cell transplant ( HSCT ) patients. Data are limited evaluating recurrence rates and risk factors for recurrence in HSCT patients. Methods HSCT patients who developed CDI between January 2010 and December 2012 were divided into 2 groups: non‐recurrent CDI (nr CDI ) and recurrent CDI ( rCDI ). Risk factors for rCDI were compared between groups. Rate of recurrence in HSCT patients was compared to that in other hospitalized patients. Results CDI was diagnosed in 95 of 711 HSCT patients (22 rCDI and 73 nr CDI ). Recurrence rates were similar in HSCT patients compared with other hospitalized patients (23.2% vs. 22.9%, P > 0.99). Patients in the rCDI group developed the index case of CDI significantly earlier than the nr CDI group (3.5 days vs. 7.0 days after transplant, P = 0.05). On univariate analysis, patients with rCDI were more likely to have prior history of CDI and neutropenia at the time of the index CDI case. Neutropenia at the time of the index CDI case was the only independent predictor of rCDI (78.8 vs. 34.8%, P = 0.006) on multivariate analysis. Conclusions The rate of rCDI was similar between HSCT and other hospitalized patients, and the majority of patients developed the index case of CDI within a week of transplantation. Neutropenia at the index CDI case may be associated with increased rates of rCDI . | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Recurrence | en_US |
dc.subject.other | Recurrent C Lostridium Difficile | en_US |
dc.subject.other | Stem Cell Transplant | en_US |
dc.title | Risk factors for recurrent C lostridium difficile infection in hematopoietic stem cell transplant recipients | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbsecondlevel | Microbiology and Immunology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/109272/1/tid12267.pdf | |
dc.identifier.doi | 10.1111/tid.12267 | en_US |
dc.identifier.source | Transplant Infectious Disease | en_US |
dc.identifier.citedreference | McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of Clostridium difficile‐ associated disease. Infect Control Hosp Epidemiol 2007; 28: 140 – 145. | en_US |
dc.identifier.citedreference | Chakrabarti S, Lees A, Jones SG, Milligan DW. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft‐versus‐host disease and non‐relapse‐mortality. Bone Marrow Transplant 2000; 26 ( 8 ): 871 – 876. | en_US |
dc.identifier.citedreference | Dubberke ER, Reske KA, Srivastava A, et al. Clostridium difficile ‐associated disease in allogeneic hematopoietic stem‐cell transplant recipients: risk associations, protective associations, and outcomes. Clin Transplant 2010; 24: 192 – 198. | en_US |
dc.identifier.citedreference | Willems L, Porcher R, Lafaurie M, et al. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2012; 18: 1295 – 1301. | en_US |
dc.identifier.citedreference | Leung S, Metzger BS, Currie BP. Incidence of Clostridium difficile infection in patients with acute leukemia and lymphoma after allogeneic hematopoietic stem cell transplantation. Infect Control Hosp Epidemiol 2010; 31: 313 – 315. | en_US |
dc.identifier.citedreference | Trifilio SM, Pi J, Mehta J. Changing epidemiology of Clostridium difficile ‐associated disease during stem cell transplantation. Biol Blood Marrow Transplant 2013; 19 ( 3 ): 405 – 409. Epub 2012 Dec 4. | en_US |
dc.identifier.citedreference | Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2012; 54 ( 8 ): 1053 – 1063. | en_US |
dc.identifier.citedreference | Eyre DW, Walker AS, Wyllie D, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012; 55 ( S2 ): S77 – S787. | en_US |
dc.identifier.citedreference | Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft‐versus‐host disease in human recipients of marrow from HL‐A‐matched sibling donors. Transplantation 1974; 18: 295 – 304. | en_US |
dc.identifier.citedreference | Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Soneshein AL. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis 2012; 55 ( S2 ): S162 – S169. | en_US |
dc.identifier.citedreference | Bodet CA 3rd, Jorgensen JH, Drutz DJ. Antibacterial activities of antineoplastic agents. Antimicrob Agents Chemother 1985; 28 ( 3 ): 437 – 439. | en_US |
dc.identifier.citedreference | Stringer AM, Gibson RJ, Bowen JM, Keefe DMK. Chemotherapy‐induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab 2009; 10 ( 1 ): 79 – 83. | en_US |
dc.identifier.citedreference | Bacon AE 3rd, Fekety R. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic‐associated diarrhea. Diagn Microbiol Infect Dis 1994; 18: 205 – 209. | en_US |
dc.identifier.citedreference | Warny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62: 384 – 389. | en_US |
dc.identifier.citedreference | Leung DY, Kelly CP, Boguniewics M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 18: 633 – 637. | en_US |
dc.identifier.citedreference | Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189 – 193. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.